ADC Therapeutics S.A. (ADCT): Price and Financial Metrics
GET POWR RATINGS... FREE!
ADCT POWR Grades
- Value is the dimension where ADCT ranks best; there it ranks ahead of 89.21% of US stocks.
- ADCT's strongest trending metric is Quality; it's been moving up over the last 177 days.
- ADCT ranks lowest in Sentiment; there it ranks in the 3rd percentile.
ADCT Stock Summary
- With a year-over-year growth in debt of -25.8%, ADC THERAPEUTICS SA's debt growth rate surpasses just 12.01% of about US stocks.
- As for revenue growth, note that ADCT's revenue has grown 829.32% over the past 12 months; that beats the revenue growth of 98.64% of US companies in our set.
- In terms of volatility of its share price, ADCT is more volatile than 89.5% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to ADC THERAPEUTICS SA are AIP, API, ATOM, GWH, and SDGR.
- Visit ADCT's SEC page to see the company's official filings. To visit the company's web site, go to www.adctherapeutics.com.
ADCT Valuation Summary
- In comparison to the median Healthcare stock, ADCT's price/sales ratio is 54.9% lower, now standing at 2.3.
- Over the past 33 months, ADCT's price/sales ratio has gone down 845.1.
Below are key valuation metrics over time for ADCT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ADCT | 2023-01-20 | 2.3 | 3.5 | -2.2 | -0.4 |
| ADCT | 2023-01-19 | 2.4 | 3.5 | -2.2 | -0.4 |
| ADCT | 2023-01-18 | 2.4 | 3.6 | -2.3 | -0.5 |
| ADCT | 2023-01-17 | 2.5 | 3.7 | -2.4 | -0.5 |
| ADCT | 2023-01-13 | 2.5 | 3.7 | -2.4 | -0.5 |
| ADCT | 2023-01-12 | 2.6 | 3.9 | -2.5 | -0.6 |
ADCT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ADCT has a Quality Grade of F, ranking ahead of 3.6% of graded US stocks.
- ADCT's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ADCT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0 | 0.963 | -0.339 |
| 2021-06-30 | 0 | 0.968 | -0.398 |
| 2021-03-31 | 0 | NA | -0.435 |
| 2020-12-31 | 0 | NA | -3.500 |
ADCT Stock Price Chart Interactive Chart >
ADCT Price/Volume Stats
| Current price | $4.92 | 52-week high | $17.89 |
| Prev. close | $5.05 | 52-week low | $2.69 |
| Day low | $4.79 | Volume | 291,400 |
| Day high | $5.17 | Avg. volume | 741,711 |
| 50-day MA | $3.84 | Dividend yield | N/A |
| 200-day MA | $6.36 | Market Cap | 377.91M |
ADC Therapeutics S.A. (ADCT) Company Bio
ADC Therapeutics SA is a clinical-stage biotechnology company, which develops antibody drug conjugates. Its products include Lonca, Cami and ADCT-602. Its drugs are used in treating various advanced solid tumors. The company was founded on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Latest ADCT News From Around the Web
Below are the latest news stories about ADC THERAPEUTICS SA that investors may wish to consider to help them evaluate ADCT as an investment opportunity.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's WhyShares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients. |
Amarin Corporation (AMRN) Down 13% in One Week: Here's WhyShares of Amarin Corporation (AMRN) fell last week as the company's largest shareholder pressurizes the company to make changes to its board of directors. |
Results from ADC Therapeutics SA (ADCT) show riskADC Therapeutics SA (NYSE:ADCT) closed Friday at $5.00 per share, down from $5.20 a day earlier. While ADC Therapeutics SA has underperformed by -3.85%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ADCT fell by -73.52%, with highs and lows ranging from $19.95 to $2.69, whereas […] |
ADC Therapeutics SA (NYSE: ADCT): It Is A Stock Worth Considering TodayIn the last trading session, 1.04 million shares of the ADC Therapeutics SA (NYSE:ADCT) were traded. Most recently the company’s share price was $5.00, and it changed around -$0.2 or -3.85% from the last close, which brings the market valuation of the company to $399.90M. ADCT currently trades at a discount to its 52-week high … ADC Therapeutics SA (NYSE: ADCT): It Is A Stock Worth Considering Today Read More » |
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a BetThe mean of analysts' price targets for ADC Therapeutics SA (ADCT) points to a 174.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
ADCT Price Returns
| 1-mo | 28.13% |
| 3-mo | 19.13% |
| 6-mo | -37.40% |
| 1-year | -69.04% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 28.13% |
| 2022 | -80.99% |
| 2021 | -36.89% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...